Selinexor: Targeting a novel pathway in multiple myeloma
CC Mo, AJ Yee, S Midha, MA Hartley‐Brown… - …, 2023 - Wiley Online Library
Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that
inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple …
inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple …
Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
S Newell, PJ van der Watt, VD Leaner - IUBMB life, 2024 - Wiley Online Library
Systemic modalities are crucial in the management of disseminated malignancies and liquid
tumours. However, patient responses and tolerability to treatment are generally poor and …
tumours. However, patient responses and tolerability to treatment are generally poor and …
[HTML][HTML] Targeting RAF dimers in RAS mutant tumors: From biology to clinic
H Yin, Q Tang, H Xia, F Bi - Acta Pharmaceutica Sinica B, 2024 - Elsevier
RAS mutations occur in approximately 30% of tumors worldwide and have a poor prognosis
due to limited therapies. Covalent targeting of KRAS G12C has achieved significant success …
due to limited therapies. Covalent targeting of KRAS G12C has achieved significant success …